Timothy Eugene Sullivan Sells 3,088 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 3,088 shares of the company’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $93,967.84. Following the transaction, the chief financial officer now owns 129,211 shares in the company, valued at $3,931,890.73. This trade represents a 2.33 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Friday, January 17th, Timothy Eugene Sullivan sold 1,730 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $29.96, for a total value of $51,830.80.
• On Monday, January 13th, Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total value of $62,279.00.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock opened at $30.00 on Friday. The stock’s 50-day moving average is $32.08 and its two-hundred day moving average is $33.18. The firm has a market cap of $3.73 billion, a price-to-earnings ratio of -14.78 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $71.90. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.17) EPS. Analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Braidwell LP boosted its stake in shares of Apellis Pharmaceuticals by 410.8% during the third quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock worth $90,130,000 after buying an additional 2,513,383 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Apellis Pharmaceuticals by 191.9% during the third quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock worth $61,845,000 after buying an additional 1,409,707 shares during the period. Jennison Associates LLC boosted its stake in shares of Apellis Pharmaceuticals by 51.6% during the fourth quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock worth $88,084,000 after buying an additional 939,289 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Apellis Pharmaceuticals by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after buying an additional 735,160 shares during the period. Finally, Sphera Funds Management LTD. acquired a new stake in shares of Apellis Pharmaceuticals during the third quarter worth about $6,226,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on APLS shares. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $26.00 price objective on shares of Apellis Pharmaceuticals in a research report on Tuesday. Oppenheimer cut their price objective on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Citigroup cut their price objective on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Wells Fargo & Company cut their price objective on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Finally, Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).